A new manuscript published in JCO Global Oncology describes the PCCTC managed IRONMAN Registry (ClinicalTrials.gov Identifier: NCT03151629), an international program recruiting diverse patients with advanced prostate cancer across academic and community practices to address unmet needs in this population. Written by Dr Lorelei A. Mucci of the Harvard T.H. Chan School of Public Health, and other investigators on behalf of the IRONMAN Global Team, the manuscript describes the development and objectives of the first international cohort of people newly diagnosed with advanced prostate cancer designed to describe variations in patient management, experiences, and outcomes. Notably, insights from IRONMAN will inform and guide future clinical management of people with mHSPC and CRPC. This cohort study will provide real-world evidence to facilitate a better understanding of the survivorship of people with advanced prostate cancer. For the full manuscript please visit ASCO Publications.
Mucci LA, Vinson J, Gold T, Gerke T, Filipenko J, Green RM, Anderson SG, Badal S, Bjartell A, Chi KN, Davis ID, Enting D, Fay AP, Lazarus J, Mateo J, McDermott R, Odedina FT, Olmos D, Omlin A, Popoola AA, Ragin C, Roberts R, Russnes KM, Waihenya C, Stopsack KH, Hyslop T, Villanti P, Kantoff PW, George DJ; IRONMAN Global Team. IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer. JCO Glob Oncol. 2022 Nov;8:e2200154. doi: 10.1200/GO.22.00154. PMID: 36332173.